Literature DB >> 18678621

Positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor: ligand interactions with distinct binding sites and evidence for a prominent role of the M2-M3 segment.

Daniel Bertrand1, Sonia Bertrand, Steven Cassar, Earl Gubbins, Jinhe Li, M Gopalakrishnan.   

Abstract

The alpha7 nicotinic acetylcholine receptor (nAChR), a homopentameric, rapidly activating and desensitizing ligand-gated ion channel with relatively high degree of calcium permeability, is expressed in the mammalian central nervous system, including regions associated with cognitive processing. Selective agonists targeting the alpha7 nAChR have shown efficacy in animal models of cognitive dysfunction. Use of positive allosteric modulators selective for the alpha7 receptor is another strategy that is envisaged in the design of active compounds aiming at improving attention and cognitive dysfunction. The recent discovery of novel positive allosteric modulators such as 1-(5-chloro-2-hydroxyphenyl)-3-(2-chloro-5-trifluoromethylphenyl)urea (NS-1738) and 1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea (PNU-120596) that are selective for the alpha7 nAChRs but display significant phenotypic differences in their profile of allosteric modulation, suggests that these molecules may act at different sites on the receptor. Taking advantage of the possibility to obtain functional receptors by the fusion of proteins domains from the alpha7 and the 5-HT(3) receptor, we examined the structural determinants required for positive allosteric modulation. This strategy revealed that the extracellular N-terminal domain of alpha7 plays a critical role in allosteric modulation by NS-1738. In addition, alpha7-5HT(3) chimeras harboring the M2-M3 segment showed that spontaneous activity in response to NS-1738, which confirmed the critical contribution of this small extracellular segment in the receptor gating. In contrast to NS-1738, positive allosteric modulation by PNU-120596 could not be restored in the alpha7-5HT(3) chimeras but was selectively observed in the reverse 5HT(3)-alpha7 chimera. All together, these data illustrate the existence of distinct allosteric binding sites with specificity of different profiles of allosteric modulators and open new possibilities to investigate the alpha7 receptor function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18678621     DOI: 10.1124/mol.107.042820

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  47 in total

1.  Nicotinic acetylcholine receptor transmembrane mutations convert ivermectin from a positive to a negative allosteric modulator.

Authors:  Toby Collins; Neil S Millar
Journal:  Mol Pharmacol       Date:  2010-05-12       Impact factor: 4.436

2.  Function of partially duplicated human α77 nicotinic receptor subunit CHRFAM7A gene: potential implications for the cholinergic anti-inflammatory response.

Authors:  Ana M de Lucas-Cerrillo; M Constanza Maldifassi; Francisco Arnalich; Jaime Renart; Gema Atienza; Rocío Serantes; Jesús Cruces; Aurora Sánchez-Pacheco; Eva Andrés-Mateos; Carmen Montiel
Journal:  J Biol Chem       Date:  2010-11-03       Impact factor: 5.157

3.  Single-channel and structural foundations of neuronal α7 acetylcholine receptor potentiation.

Authors:  Corrie J B daCosta; Chris R Free; Jeremías Corradi; Cecilia Bouzat; Steven M Sine
Journal:  J Neurosci       Date:  2011-09-28       Impact factor: 6.167

4.  Critical Molecular Determinants of α7 Nicotinic Acetylcholine Receptor Allosteric Activation: SEPARATION OF DIRECT ALLOSTERIC ACTIVATION AND POSITIVE ALLOSTERIC MODULATION.

Authors:  Nicole A Horenstein; Roger L Papke; Abhijit R Kulkarni; Ganesh U Chaturbhuj; Clare Stokes; Khan Manther; Ganesh A Thakur
Journal:  J Biol Chem       Date:  2016-01-07       Impact factor: 5.157

5.  Desformylflustrabromine (dFBr) and [3H]dFBr-Labeled Binding Sites in a Nicotinic Acetylcholine Receptor.

Authors:  Ayman K Hamouda; Ze-Jun Wang; Deirdre S Stewart; Atul D Jain; Richard A Glennon; Jonathan B Cohen
Journal:  Mol Pharmacol       Date:  2015-04-13       Impact factor: 4.436

6.  NMR structures of the human α7 nAChR transmembrane domain and associated anesthetic binding sites.

Authors:  Vasyl Bondarenko; David D Mowrey; Tommy S Tillman; Edom Seyoum; Yan Xu; Pei Tang
Journal:  Biochim Biophys Acta       Date:  2013-12-31

Review 7.  Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system.

Authors:  Antoine Taly; Pierre-Jean Corringer; Denis Guedin; Pierre Lestage; Jean-Pierre Changeux
Journal:  Nat Rev Drug Discov       Date:  2009-09       Impact factor: 84.694

8.  The chimeric gene CHRFAM7A, a partial duplication of the CHRNA7 gene, is a dominant negative regulator of α7*nAChR function.

Authors:  Tanguy Araud; Sharon Graw; Ralph Berger; Michael Lee; Estele Neveu; Daniel Bertrand; Sherry Leonard
Journal:  Biochem Pharmacol       Date:  2011-06-28       Impact factor: 5.858

9.  Heteromeric Neuronal Nicotinic Acetylcholine Receptors with Mutant β Subunits Acquire Sensitivity to α7-Selective Positive Allosteric Modulators.

Authors:  Clare Stokes; Sumanta Garai; Abhijit R Kulkarni; Lucas N Cantwell; Colleen M Noviello; Ryan E Hibbs; Nicole A Horenstein; Khalil A Abboud; Ganesh A Thakur; Roger L Papke
Journal:  J Pharmacol Exp Ther       Date:  2019-06-07       Impact factor: 4.030

10.  Colchicine: a novel positive allosteric modulator of the human 5-hydroxytryptamine3A receptor.

Authors:  A N de Oliveira-Pierce; R Zhang; T K Machu
Journal:  J Pharmacol Exp Ther       Date:  2009-02-02       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.